Date: 2017-05-03
Type of information: Nomination
Compound: chief medical officer
Company: Gensight Biologics (France)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 3, 2017, GenSight Biologics announced it has appointed Mohamed Genead, M.D., as Chief Medical Officer, effective May 1, 2017. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen. Prior to Biogen, he served eight years at Allergan as the Executive Medical Director, Global Clinical Development for the Ophthalmology/Retina Therapeutic Area.
- In this new position, Dr. Genead’s responsibilities will include setting strategy for and execution of global clinical development programs, management of the Company’s medical affairs, clinical operations and biostatistics departments. He will be part of the Executive Committee and will report directly to Bernard
Gilly, PhD, Chief Executive Officer of GenSight. Dr. Genead will be based on the East Coast of the United States.
Financial terms:
Latest news:
Is general: Yes
